{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:48:52Z","timestamp":1766173732179,"version":"3.48.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":320,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101038","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:35:06Z","timestamp":1763638506000},"page":"101038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epidemiology and treatments of neuroendocrine prostate cancer in a large commercially insured population in the US"],"prefix":"10.1016","volume":"45","author":[{"given":"Zdravko","family":"Vassilev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qayyim","family":"Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasreen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal","family":"Barel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorelei","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Lunacsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2025.101038_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101038_bib0002","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030411","article-title":"Histopathology of Prostate Cancer","volume":"7","author":"Humphrey","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101038_bib0003","first-page":"742","article-title":"Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms","volume":"3","author":"Verma","year":"2020","journal-title":"Cancer Drug Resist"},{"issue":"8","key":"10.1016\/j.ctarc.2025.101038_bib0004","doi-asserted-by":"crossref","first-page":"T51","DOI":"10.1530\/ERC-21-0002","article-title":"The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches","volume":"28","author":"Labrecque","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"15","key":"10.1016\/j.ctarc.2025.101038_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025237","article-title":"Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101038_bib0006","doi-asserted-by":"crossref","first-page":"128","DOI":"10.21037\/tau-22-867","article-title":"Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series","volume":"12","author":"Qi","year":"2023","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101038_bib0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2012.4","article-title":"A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008","volume":"15","author":"Marcus","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2025.101038_bib0008","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.21037\/tcr.2017.01.20","article-title":"Neuroendocrine differentiation in prostate cancer: key epigenetic players","volume":"6","author":"Gupta","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"24","key":"10.1016\/j.ctarc.2025.101038_bib0009","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: a Multi-institutional Prospective Study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101038_bib0010","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101038_bib0011","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and Biological Features of Neuroendocrine Prostate Cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101038_bib0012","first-page":"4145","article-title":"Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer","volume":"35","author":"Alanee","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101038_bib0013","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2003.11.032","article-title":"Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy","volume":"45","author":"Hirano","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101038_bib0014","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101038_bib0015","doi-asserted-by":"crossref","first-page":"IJE20","DOI":"10.2217\/ije-2019-0008","article-title":"Treatment-Emergent Neuroendocrine Prostate Cancer: molecularly Driven Clinical Guidelines","volume":"6","author":"Clermont","year":"2019","journal-title":"Int J Endocr Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101038_bib0016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","article-title":"Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation","volume":"14","author":"Franceschini","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2025.101038_bib0017","article-title":"Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality","author":"Siech","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"30","key":"10.1016\/j.ctarc.2025.101038_bib0018","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2025.101038_bib0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2025.101038_bib0021","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"journal-title":"Janssen","article-title":"Prescribing information","year":"2017","key":"10.1016\/j.ctarc.2025.101038_bib0022"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101038_bib0023","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101038_bib0024","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.ctarc.2025.101038_bib0025","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101038_bib0026","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101038_bib0027","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101038_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e25728","article-title":"Association between Charlson comorbidity index and survival outcomes in patients with prostate cancer: a meta-analysis","volume":"10","author":"Cui","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101038_bib0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:45:11Z","timestamp":1766173511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"alternative-id":["S2468294225001741"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101038","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and treatments of neuroendocrine prostate cancer in a large commercially insured population in the US","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101038"}}